cisplatin,pembrolizumab,gemcitabine,pemetrexed
merck
['kn-789', 'kn-671']
 short answer: nobody knows. i certainly don't. but i think we should note this isn't isolated finding (e.g., seen in kn-671 as well) &amp; take a step back in speaking definitively about pts w/egfr mut'n categorically not benefiting from immunotherapy. (hard to reconcile w/kn-789).
Med Onc,@CityofHope; VP Netwk Strategy AccessHope, Founder,@CancerGRACE; Web Ed,@JAMAOnc; Author/Ed, @UptoDate

Telemed/digital med fan. 
Disclosures @ website